Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II, Open-label, Multicenter Study of Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First-line Therapy in Metastatic Microsatellite-stable Colorectal Cancer (COLUMBIA-1)

NCT04068610 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT04068610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04068610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II, Open-label, Multicenter Study of Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First-line Therapy in Metastatic Microsatellite-stable Colorectal Cancer (COLUMBIA-1)
Lead sponsor
MedImmune LLC
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
September 13, 2019
Completion date
November 24, 2026
Enrollment
61 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic microsatellite-stable colorectal cancer